TMS CoTSE:4891 -0.96%32 Pretax Margin % is % as of Dec. 2025. GuruFocus rates TSE:4891 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 938 Biotechnology companies, TMS Co ranks worse than 106609.7% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. TMS Co's Pre-Tax Income for the
three
months ended in Dec. 2025 was 円0.00 Mil. TMS Co's Revenue for the
three
months ended in Dec. 2025 was 円0.00 Mil. Therefore, TMS Co's pretax margin for the quarter that ended in Dec. 2025 was %.
The historical rank and industry rank for TMS Co's Pretax Margin % or its related term are showing as below:
TSE:4891's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.375 * Ranked among companies with meaningful Pretax Margin % only.
TMS Co (TSE:4891) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
TMS Co Pretax Margin % Related Terms
TMS Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for TMS Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4891 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, TMS Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMS Co Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TMS Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where TMS Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMS Co (TSE:4891) has a Pretax Margin % of % as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TMS Co and its competitors. Over the past decade, TMS Co's Pretax Margin % has ranged from 55.45 to 55.45. According to the industry distribution chart, TMS Co ranks #999999 out of 938 companies in the Biotechnology industry.
Is TMS Co's Pretax Margin % too high?
TMS Co's current Pretax Margin % is %. Over the past 10 years, this metric has ranged from a low of 55.45 to a high of 55.45. Based on the distribution chart, TMS Co ranks #999999 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, TMS Co has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does TMS Co's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TMS Co ranks #999999 out of 938 companies for Pretax Margin %. This places TMS Co in the lower half of its industry. Historically, TMS Co's own Pretax Margin % has ranged from 55.45 to 55.45 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on TMS Co and its competitors. TMS Co's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMS Co stock overvalued right now?
TMS Co (TSE:4891) has a current Pretax Margin % of %. The current Pretax Margin % is %. TMS Co's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For TMS Co (TSE:4891), the current Pretax Margin % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
32GF Score
Get the complete analysis for TSE:4891
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4891 has been successfully added to your 
